CalciMedica (NASDAQ:CALC – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect CalciMedica to post earnings of ($0.48) per share for the quarter.
CalciMedica Trading Down 3.3 %
CALC opened at $2.04 on Thursday. The company’s 50 day moving average is $2.52 and its 200-day moving average is $3.29. CalciMedica has a 1-year low of $1.83 and a 1-year high of $6.27. The company has a market cap of $27.50 million, a P/E ratio of -1.89 and a beta of 1.20.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a research note on Tuesday, March 4th.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Articles
- Five stocks we like better than CalciMedica
- The Risks of Owning Bonds
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- How to Invest in Blue Chip Stocks
- Alphabet’s Officially In A Bear Market—Time To Buy?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
